Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

MRNA's earnings and revenues surpass estimates in the fourth quarter of 2024. The company reiterates 2025 total revenue ...

The U.S. Food and Drug Administration (FDA) has just made the explosive admission that Covid mRNA “vaccines” are spiked with ...

A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...

The Senate officially confirmed Robert F. Kennedy Jr.'s nomination as secretary of Health and Human Services on Thursday. The final vote count was 52 in favor and 48 against, with Sen. Mitch McConnell ...

All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...

Feb. 5, 2025 — Researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful ...

Laura is an editor and staff writer at IFLScience. She obtained her Master's in Experimental Neuroscience from Imperial College London.

Dr. Paulo H. Verardi, a virologist and head of the Department of Pathobiology and Veterinary Science at the University of ...

Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...